Epizyme Reports Positive Interim Data

June 14, 2017

Shares of Epizyme were down almost 15% pre-market Wednesday even though the biopharmaceutical firm reported positive interim data from a phase 2 clinical trial of tazemetostat to treat relapsed or refractory patients with follicular lymphoma (FL), or diffuse large B-cell lymphoma (DLBCL) grouped by EZH2 mutational status.

“I believe that tazemetostat may play a significant role in disease management for my patients, and am particularly excited by the impact observed in patients with follicular lymphoma,” said Franck Morschhauser, lead investigator of the study. “Tazemetostat has demonstrated a uniquely tolerable safety profile, and I look forward to further exploring its full benefit in patients with relapsed or refractory FL and DLBCL as the data mature.”

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

By Stephen Holmes

Free Email Newsletter


Enter your email address below to get the latest news and analysts' ratings for your stocks with MarketBeat's FREE daily email newsletter: